Effect Of Semaglutide In Coronary Atheroma Plaque

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Atheroscleroses, Coronary

Interventions

DRUG

Semaglutide

Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly

All Listed Sponsors

lead

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

OTHER